相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen
Yunfei Wang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant
Caroline R. Champion
ANNALS OF PHARMACOTHERAPY (2021)
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman et al.
CELL HOST & MICROBE (2021)
Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response
Qiu-Dong Su et al.
VACCINE (2021)
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Jing-Hui Tian et al.
NATURE COMMUNICATIONS (2021)
Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
Cong Xu et al.
SCIENCE ADVANCES (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhiwei Wu et al.
LANCET INFECTIOUS DISEASES (2021)
Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics
Dapeng Zhou et al.
GLYCOBIOLOGY (2021)
Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA
Alyse D. Portnoff et al.
VACCINES (2020)
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
Chek Meng Poh et al.
NATURE COMMUNICATIONS (2020)
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
Wen-Hsiang Chen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
Eun Kim et al.
EBIOMEDICINE (2020)
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Lianpan Dai et al.
CELL (2020)
A Thermostable mRNA Vaccine against COVID-19
Na-Na Zhang et al.
CELL (2020)
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Dorottya Laczko et al.
IMMUNITY (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
Shuo Du et al.
CELL (2020)
Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
Yang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett et al.
NATURE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Ching-Lin Hsieh et al.
SCIENCE (2020)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
Brian J. Ward et al.
LANCET (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma
Lluc Farrera-Soler et al.
PLOS ONE (2020)
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Sandhya Bangaru et al.
SCIENCE (2020)
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Mimi Guebre-Xabier et al.
VACCINE (2020)
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
Xianglei Liu et al.
VACCINE (2020)
A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade
Brigette N. Corder et al.
VIRUSES-BASEL (2020)
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Wen-Hsiang Chen et al.
VACCINE (2020)
CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization
Brien K. Haun et al.
FRONTIERS IN IMMUNOLOGY (2020)
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates
Tingting Li et al.
EMERGING MICROBES & INFECTIONS (2020)
Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection
Xiaoxiao Qi et al.
CHEMICAL COMMUNICATIONS (2020)
An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines
Michael I. Hauser et al.
VACCINE (2019)
Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
Sarah Schillie et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
Lisa M. Dunkle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers
Limin Wijaya et al.
VACCINE (2017)
A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen
Shirin Kalimuddin et al.
VACCINE (2017)
GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial
Pierre Van Damme et al.
CLINICAL CANCER RESEARCH (2016)
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine
Shelly Senders et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children
Jorgen Stassijns et al.
VACCINE (2016)
A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies
Yi Zhang et al.
VIROLOGY (2016)
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial
Matti Lehtinen et al.
VACCINE (2015)
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine
Alain Luxembourg et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination
Josianne Nitcheu Tefit et al.
VACCINE (2014)
Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population
Jacob Atsmon et al.
VACCINE (2014)
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 1826years
Hiroyuki Yoshikawa et al.
CANCER SCIENCE (2013)
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE plus GLA) adjuvant
John J. Treanor et al.
VACCINE (2013)
Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
Nathalie Garcon et al.
BIODRUGS (2011)
An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice
Yuk-Fai Lau et al.
JOURNAL OF VIROLOGY (2010)
Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice
Yuk-Fai Lau et al.
VIROLOGY (2010)
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine - A randomized controlled trial
John J. Treanor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults
JJ Treanor et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study
CL Cooper et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
SA Halperin et al.
VACCINE (2003)
分享论文
